Measles virus (MV), a human pathogen, uses the signaling lymphocyte activation molecule (SLAM) or CD46 as an entry receptor. Although several transgenic mice expressing these receptors have been generated as small animal models for measles, these mice usually have to be made defective in IFN-α/β signaling to facilitate MV replication. Similarly, when functional receptors are expressed by transfection, mouse cells do not allow MV growth as efficiently as primate cells. In this study, we demonstrate that MV efficiently grows in SLAM-expressing mouse cells in which the Sendai virus (SeV) C protein is transiently expressed. We developed a SLAM-expressing mouse cell line whose genome also encodes the SeV C protein downstream of the sequence flanked with loxP sequences. When this cell line was infected with the recombinant MV expressing the Cre recombinase, the SeV C protein was readily expressed. Importantly, the Cre recombinase-encoding MV grew in this cell line much more efficiently than it did in the parental cell. The minigenome assay demonstrated that the SeV C protein does not modulate MV RNA synthesis. Analyses using the mutant proteins with the defined functional defects revealed that the IFN-antagonist function, but not the budding-accelerating function, of the SeV C protein was critical for supporting efficient MV growth in mouse cells. Our results indicate that insufficient IFN antagonism can be an important determinant of the host range of viruses, and the system described here may be useful to overcome the species barrier of other human viruses.
interferon | innate immunity | paramyxovirus M easles is an acute contagious human disease characterized by high fever and a maculopapular rash (1) . Measles virus (MV), its causative agent, is an enveloped virus classified as a member of the genus Morbillivirus in the family Paramyxoviridae, the order Mononegavirales. The virus has a nonsegmented negative-sense RNA genome that contains six genes encoding the nucleocapsid (N), phospho-(P), matrix, fusion, hemagglutinin (H), and large (L) proteins, respectively. The P gene encodes additional gene products, termed the V and C proteins, via an RNA editing and alternative translational initiation in a different reading frame, respectively (2, 3) . The V and C proteins have been shown to counteract host innate immune responses and play important roles in MV virulence in vivo (1, 4) . The V protein directly inhibits induction (5) and signaling (6-8) of IFN-α/β, and the C protein suppresses the host IFN response by modulating viral RNA synthesis (9) (10) (11) .
The human signaling lymphocyte activation molecule (SLAM, also called CD150) acts as a cellular receptor for MV (12) , and vaccine strains can use CD46 as an alternative receptor because of the amino acid (aa) changes in their attachment H protein (13, 14) . Several transgenic or knock-in mice expressing human SLAM or CD46 have been generated as small animal models for measles (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) . To facilitate MV replication, these mice usually have to be made defective in IFN signaling (16, (18) (19) (20) or used when they are newly born (15, 17) . Similarly, when human SLAM or CD46 is expressed by transfection, rodent cells become susceptible to MV, but do not allow MV growth as efficiently as primate cells (14, 26) . The restriction of MV growth in rodents may involve blockades at different steps of the virus replication cycle (26, 27) .
Sendai virus (SeV, also known as murine parainfluenza virus 1), a member of the genus Respirovirus in the family Paramyxoviridae, infects epithelial cells in the respiratory tract and causes bronchopneumonia in rodents (28) . Like that of MV, its P gene encodes virulence factor proteins in addition to the P protein. These proteins are C9, C, Y1, Y2 (collectively referred to as the C proteins), V, and W proteins. The four C proteins are translated from a +1 reading frame relative to the P reading frame using alternative start codons. V and W mRNAs are produced by insertion of one and two guanine residues at a specific position during transcription, respectively. The SeV C proteins are nonessential for virus replication but play important roles in viral propagation in vivo (29) . Several functions of the SeV C protein have been documented. First, it physically associates with signal transducers and activator of transcription (STAT) 1, and inhibits tyrosine phosphorylation of STAT1 and STAT2 and dephosphorylation of STAT1, thereby blocking the IFN signaling pathway (30) . Second, it inhibits virus-induced apoptosis, which is probably mediated by the IFN signaling pathway (31) . Third, it modulates viral RNA synthesis through its interaction with the viral polymerase L protein (32) (33) (34) . Fourth, it enhances the SeV budding by recruiting Alix/AIP1, a cellular protein involved in apoptosis and endosomal trafficking, to the plasma membrane (35, 36) . In the absence of the C protein, there is a significant delay in the incorporation of SeV structural proteins into progeny virions (37) . The C9, Y1, and Y2 proteins share all or some of these functions with the C protein (38, 39) . For example, the Y1 protein, which has the common carboxyl terminus with the C protein but is 23 aa shorter in length, does not have the ability to enhance the viral budding (36) but is fully functional in antagonizing the host IFN response and regulating viral RNA synthesis (30, 40) .
Mutants of the SeV C protein lacking its different functions have been described. The mutant Cm5 has aa substitutions K151A, E153A, and R154A, whereas Cm* has substitutions K151A, E153K, and R157L (41, 42) . These C-protein mutants no longer possess the ability to bind STAT1 and IFN-antagonist activity. The mutant d194 has 10-aa truncation at the carboxyl terminus, and therefore cannot interact with AIP1/Alix (35) ; this eliminates the budding-accelerating function.
In this study, we addressed why MV cannot grow efficiently in mice possessing functional receptors. To test the hypothesis that MV lacks some factors allowing its efficient growth in mouse cells, we examined the effects of the SeV C protein and its mutants on MV growth in mouse cells. We also developed the Cre-loxP expression system for the SeV C protein in which the Cre recombinase-expressing recombinant MV induces the expression of the SeV C protein in infected mouse cells. Our results indicate that insufficient IFN antagonism is responsible for restricted MV growth in mouse cells.
Results
Effect of the SeV C Protein on MV Growth in Mouse Cell Lines. We reasoned that MV, a human virus, lacks some factors allowing its efficient growth in mouse cells, which mouse viruses may naturally possess. To test this contention, we examined whether the expression of the SeV C protein, a pleiotropic protein, can alleviate restriction of MV growth in mouse cells. Four cell lines expressing human SLAM were used for this experiment: mouse cell lines NIH 3T3/hSLAM and L/hSLAM and human cell lines HeLa/hSLAM and HEK293/hSLAM. These cell lines were transiently transfected with the expression plasmid encoding the SeV C protein or the empty vector, and then infected with the recombinant MV encoding the reporter Renilla luciferase (MVLuci) (43) . Luciferase activities obtained with MV-Luci infection correlate well with levels of MV multiplication (Fig. S1 ). Transient expression of the SeV C protein resulted in 20-and fivefold increased luciferase activities in NIH 3T3/hSLAM and L/ hSLAM cells, respectively, compared with those in cells transfected with the empty vector (Fig. 1A) . In contrast, luciferase activities were increased only marginally in human cell lines transfected with the SeV C protein (Fig. 1A) , even though human cell lines produced higher levels of the SeV C protein after transfection than mouse cell lines (Fig. 1B) .
MV produces C and V proteins analogous to the SeV C protein. To address the possibility that the MV C and V proteins are not sufficiently expressed in MV-infected mouse cells, we examined whether these proteins expressed through transfection can promote MV growth in mouse NIH 3T3/hSLAM cells. Unlike that of the SeV C protein, the plasmid-mediated expression of the MV C or V protein did not increase luciferase activity at all (Fig. 1C) . These results indicate that the SeV C protein has an ability to support efficient MV growth in mouse cells, whereas the MV C and V proteins do not.
Development of a Cre-loxP-Mediated Expression System for the SeV C Protein. To examine the growth kinetics of MV in the presence of the SeV C protein, we attempted to establish mouse cell lines stably expressing the protein. However, such cell lines were not successfully obtained, presumably because continuous expression of the SeV C protein may be detrimental to cells. Therefore, we decided to develop a Cre-loxP-mediated expression system for the SeV C protein. The DNA fragment encoding the SeV C protein was inserted downstream of the puromycin-resistant gene flanked with loxP sequences in the eukaryotic expression vector pCA7 (44) ( Fig. 2A ). This plasmid, pCA7-loxP-SC, directed the expression of the SeV C protein only when the plasmid encoding the Cre recombinase (pCA7-Cre) was cotransfected (Fig. 2B ). Although the SeV C gene used in this study can direct the expression of the Y1 and Y2 proteins in addition to the C protein, Western blot analysis revealed that the Y1 and Y2 proteins were expressed in trace amounts, if any. Luciferase activity of MV-Luci-infected NIH 3T3/hSLAM cells was greatly increased when both pCA7-loxP-SC and pCA7-Cre plasmids were cotransfected, whereas that of infected HeLa/hSLAM cells was not (Fig. 2C) . These results show that the SeV C protein expressed via the Cre-loxP system can enhance MV growth in mouse cells. The structure of the expression plasmid pCA7-loxP-SC is shown. CAG promoter, the strong eukaryotic promoter of pCA7. Puro R , the puromycin resistance gene. polyA, polyA signal sequence. 3× polyA, polyA signal sequences tandem repeated three times. SeV-C, the gene encoding the SeV C protein. In the presence of the Cre recombinase, the DNA fragment between loxP sequences is removed and the SeV C protein is expressed. Filled triangles indicate the restriction enzyme sites used for the generation of 3SC cells (Fig. 4). (B) 293T cells were transfected with pCA7-SeV-C, pCA7-Cre, pCA7-loxP-SC, and pCA7 in various combinations. +, the plasmid included for transfection; −, not included. Total amounts of transfected plasmids (500 ng) were adjusted by pCA7. At 48 h posttransfection, the cells were lysed and the lysates were subjected to SDS/PAGE and Western blotting for the detection of the Cre recombinase and SeV C protein. 
Generation of Recombinant MVs
the SeV C protein more usable, we generated recombinant MVs possessing a transcriptional unit of the Cre recombinase by reverse genetics. The Cre recombinase gene was inserted at two different positions of the MV genome (in front of the N gene for the recombinant MV-Cre and between the H and L genes for the recombinant MV-addCre) so that optimal expression levels of the protein could be achieved (Fig. 3A) . HeLa/hSLAM cells were infected with MV-Cre, MV-addCre, or MV expressing the enhanced GFP (MV-EGFP) (45) , and the proteins from infected cells were analyzed by SDS/PAGE and Western blotting (Fig. 3B) . The MV N protein was expressed comparably in cells infected with the three recombinant MVs, indicating that these viruses grew at similar levels in HeLa/hSLAM cells. EGFP encoded in the first transcriptional unit of MV-EGFP and MV-addCre was also expressed comparably in cells infected with these two viruses. In contrast, the Cre recombinase was expressed in cells infected with MV-Cre w3.5 times higher than it was in those infected with MV-addCre, consistent with the 39 to 59 decreasing gradient of viral transcripts levels common to the order Mononegavirales (28, 46) . Growth kinetics of these recombinant MVs was analyzed in African green monkey Vero/hSLAM cells (47) . All these viruses grew similarly until 48 h postinfection and reached their peak titers at 48 or 72 h postinfection (Fig. 3C) . At later time points, MV-Cre grew even better than MV-EGFP. The results indicate that the expression of the Cre recombinase does not greatly affect MV replication in permissive primate cells.
Growth of Cre-Recombinase-Expressing MV in Mouse Cells in Which the SeV C Protein Is Expressed via the Cre-loxP System. To generate mouse cells in which the SeV C protein is expressed via the CreloxP system, NIH 3T3/hSLAM cells were transfected with the DNA fragment containing the SeV C gene produced by digesting pCA7-loxP-SC with SspI and PstI ( Fig. 2A) , and a stable clone named 3SC was obtained by selecting transfected cells in culture medium containing 2 μg/mL of puromycin. NIH 3T3/hSLAM and 3SC cells were infected with MV-EGFP and MV-Cre, and protein expressions in them were examined at 36 h postinfection. The SeV C protein was detected only in 3SC cells infected with MV-Cre (Fig. 4A) . Accordingly, the MV N protein was expressed at a higher level in MV-Cre-infected 3SC cells, compared with 3SC cells infected with MV-EGFP or NIH 3T3/hSLAM cells infected with either of these viruses. Importantly, phosphorylation of STAT1 was also suppressed in MV-Cre-infected 3SC cells (Fig. 4A) , consistent with the IFN-antagonist function of the SeV C protein (48) .
Growth kinetics of MV-EGFP was almost identical in NIH 3T3/ hSLAM and 3SC cells (Fig. 4B) , indicating that 3SC cells do not have any adventitious changes affecting MV replication (other than the presence of the SeV C gene). In contrast, MV-Cre and MV-addCre grew much more efficiently in 3SC cells than they did in NIH 3T3/hSLAM cells. The peak titers of MV-Cre and MVaddCre were about 50-and 100-times higher in 3SC cells than those in NIH 3T3/hSLAM cells, respectively. Furthermore, the peak titer of MV-Cre in 3SC cells was 20-times higher than that of MV-EGFP (2 × 10 5 pfu/mL vs. 10 4 pfu/mL). It was notable that MV-Cre and MV-addCre continued to replicate in 3SC cells until the end of the assay (infectious centers were still present among normal-appearing cells at 120 h postinfection), whereas growth of MV-EGFP declined rapidly after it had reached the peak (at 48 h postinfection) and the virus titer became below the detection level at 96 h postinfection (when there were only normal-appearing cells with no infectious centers).
Role of IFN-Antagonist Function of the SeV C Protein in Supporting
Efficient MV Growth in Mouse Cells. The SeV C protein has multiple functions to promote virus replication. To determine which function of the SeV C protein is critical for supporting efficient MV growth in mouse cells, the mutants lacking its different functions were studied.
NIH 3T3/hSLAM cells were transfected with various amounts (25, 100, and 400 ng) of expression plasmids encoding the wildtype C protein, Y1 protein, or mutants described above. At 48 h posttransfection, part of the respective samples was examined by SDS/PAGE and Western blot analysis, and the remainder was infected with MV-Luci. All of the proteins had comparable levels of expression, except d194, which was detected at a lower level than others (Fig. 5A) . The expression of the C or Y1 protein resulted in increased luciferase activities in a dose-dependent manner, as measured at 48 h postinfection (Fig. 5B) . In contrast, the expression of the Cm5, Cm*, or d194 protein did not lead to the enhancement of the reporter gene expression. Because the Y1 protein, which does not promote viral budding, effectively enhanced MV growth in mouse cells, we suspected that d194 fails to inhibit the IFN-signaling pathway, which we confirmed in L929 cells (Fig. S2) . The minimal amount (25 ng) of the expression plasmid used was sufficient for the SeV C protein to increase the reporter gene expression (Fig. 5B) . The expression levels of Cm5, Cm*, and d194 proteins as produced with 400 ng each of expression plasmids were higher than that of the SeV C protein as produced with 25 ng of the expression plasmid (Fig.  5A) . Thus, we concluded that these three mutant proteins cannot enhance MV growth in mouse cells.
The SeV C protein is also known to have the ability to modulate SeV RNA synthesis (32) (33) (34) . To examine the possible effect of the SeV C protein on MV RNA synthesis, the minigenome assay was performed. Consistent with previous reports (10, 11, 49, 50) , the inclusion of the MV C protein in the assay reduced the expression level of the reporter gene (Fig. 5C) . The SeV C protein did not inhibit MV RNA synthesis, but rather slightly enhanced the minigenome expression (Fig. 5C ).
Taken together, these results indicate that IFN-antagonist activity of the SeV C protein, but not its ability to promote viral budding or modulate viral RNA synthesis, is critical for supporting efficient MV growth in mouse cells. The importance of IFN antagonism in enhancing MV growth in mouse cells was also revealed by using the influenza virus NS1 protein (Fig. S3) . The MV V protein is known to block IFN signaling (6) (7) (8) , like the SeV C protein. Therefore, we examined whether the MV V protein can inhibit IFN signaling in mouse cells. Although the SeV C protein inhibited IFN signaling in both human 293T and mouse L929 cells, the MV V protein was found to do so in human cells, but not in mouse cells (Fig. 5D) .
Discussion
In the present study, we have shown that the SeV C protein has an ability to enhance MV growth in SLAM-expressing mouse cells, and that its IFN-antagonist function is critical for this ability. We initially directed our attention to the SeV C protein because it plays important roles in SeV propagation in mice (42) . Among multiple functions of the SeV C protein, IFN antagonism has been well investigated. The carboxyl terminal half of the SeV C protein is sufficient to inhibit IFN action (40) , and only 14-aa truncation from the carboxyl terminus of the protein diminishes this function (51) . In this study, we demonstrated that the mutant d194 that cannot interact with Alix/AIP1 and facilitate viral budding (35) also fails to inhibit the IFN-signaling pathway and enhance MV replication in mouse cells. Thus, 10-aa truncation in the carboxyl terminus not only prevents the SeV C protein from promoting viral budding, but also from counteracting the host IFN response. The SeV C protein can reduce viral RNA synthesis through its binding with the viral RNA polymerase L protein (32, 33) and regulate the balance between sense and antisense viral genome RNAs (34) . However, our results indicated that the SeV C protein could not reduce the reporter gene expression in the MV minigenome assay. Therefore, enhancement of MV growth in mouse cells is unlikely to be caused by the ability of the SeV C protein to modulate viral RNA synthesis.
We showed that transient expression of the SeV C protein did not result in increased reporter gene expression in MV-Luciinfected human cells. Does this mean that the SeV C protein cannot antagonize the human IFN response? Many groups have shown that the SeV C protein is capable of inhibiting IFN action in human cell lines (30); we also demonstrated that it is indeed the case (Fig. 5D) . Therefore, it is likely that the SeV C protein To what extent its IFN antagonists V, C, and P proteins can interact with their target protein counterparts in mouse cells remain to be defined. Thus, in addition to cellular receptors, the ability to counteract the host IFN response is an important determinant for the host range of MV (15, (18) (19) (20) 23 ).
Other host factors may also play roles in determining the host range. This question can be answered by examining whether mice supplied with a receptor and the SeV C protein reproduce human disease after MV infection. It seems to be straightforward to generate the recombinant MV possessing the SeV C gene and infect mouse cell lines or genetically modified mice expressing receptors with this virus. However, we did not attempt to do it. As mentioned above, the SeV C protein has the ability to inhibit both human and mouse IFN responses, and there is a potential risk that such a recombinant MV will be more virulent for humans than field-circulating MVs. We should keep this in mind even though, in human cell lines, expression of the SeV C protein did not greatly enhance MV growth. Accordingly, we developed the Cre-loxP-mediated expression system for the SeV C protein. Our intention was to make infected cells more permissive to MV rather than to make the virus more virulent. In mouse cells infected with the Cre recombinase-expressing MV, the enzyme catalyzes the recombination at loxP sequences, thereby allowing the SeV C protein to be expressed, which will in turn lead to efficient MV growth. On the other hand, uninfected mouse cells do not express the SeV C protein, and their IFN system remains intact. In this way, we should be able to study MV infection in mice without totally compromising the IFN system. Generation of transgenic mice stably expressing the SeV C protein has not been reported like stable cell lines, probably because of the deleterious effect of its continuous expression. Because human cell lines stably expressing the protein have been obtained (40, 51) , the effect may be specific to mice. Our present data warrant the generation of a new mouse model for MV infection, based on our conditional Cre-loxP expression system, and this approach is now under way. Furthermore, this system is readily applicable to other human viruses, such as hepatitis C virus, that do not grow well in immunocompetent mice (52) .
Materials and Methods
For MV minigenome assay, monolayers of VV5-4 cells (53) cultured in 24-well cluster plates were infected with vTF7-3 (54) at a multiplicity of infection (MOI) of 0.5, and then transfected with the MV minigenome plasmid p18MGFLuc01 encoding the firefly luciferase gene and support plasmids expressing the MV N, P, and L proteins, respectively (55), together with pCA7 or pCA7-SeV-C or pCA7-MV-C (10), using Lipofectamine 2000 reagent (Invitrogen Life Technologies). At 48 h posttransfection, enzymatic activities of the luciferase were measured. To perform reporter assay for the inhibition of IFN-α signaling, cells were transfected with pISRE-Luc (56) and pRL-TK (Promega), together with pCA7, pCA7-SeV-C, or pCA7-MV-VΔC (10), using Lipofectamine 2000. At 36 h posttransfection, the medium was changed to one supplemented, or not, with 1,000 IU/mL IFN-αA/D (Sigma). After a further 8 h of incubation, the relative luciferase activities were determined by dividing the firefly luciferase activity of IFN-α-treated cells by that of untreated cells. Transfection efficiencies of different samples were normalized against the Renilla luciferase activity, which is regulated by the herpes simplex virus thymidine kinase promoter, and therefore unaffected by IFN treatment. Detailed materials and methods are described in SI Materials and Methods.
